2 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 2, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Non-small Cell Carcinoma: new trials by email Literature Review of Non-small Cell Carcinoma trials Research Report on Non-small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab - Non-small Cell Lung Cancer, Non-small Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Alexander Chi | 83 | 2023-10-09 | 2023-10-03 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy - Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 68 | 2022-12-09 | 2026-05-07 |
| Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC Ramucirumab, Atezolizumab, N-803 - Non-small Cell Lung Cancer, Non-small Cell Carcinoma | Phase 2 | Withdrawn | Washington University School of Medicine | 2021-10-31 | 2021-11-05 | |
| Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer Zimberelimab, Domvanalimab, Etrumadenant - Non Small Cell Lung Cancer, Non-small Cell Carcinoma | Phase 2 | Active not recruiting | Washington University School of Medicine | 30 | 2021-08-04 | 2026-11-09 |
| Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Induction Durvalumab, Chemotherapy, Radiation - Lung Cancer, Non-small Cell Carcinoma | Phase 2 | Terminated | Rachel Sanborn | 10 | 2020-06-18 | 2024-12-20 |
| Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer intrapleural docetaxel administration - Pleural Effusion, Malignant, Non-small Cell Carcinoma | Phase 2 | Completed | Asan Medical Center | 4 | 2016-07-26 | 2019-03-08 |
| Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Drug: Hyperacute Lung Cancer Cell Vaccine - Non-small Cell Carcinoma, Adenocarcinoma of Lung | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 54 | 2003-11-01 | 2020-05-28 |
Carcinoma, Non-Small-Cell Lung (6) · Lung Neoplasms (2) · Adenocarcinoma of Lung (1) · Anus Neoplasms (1) · Carcinoma, Large Cell (1) · Carcinoma, Small Cell (1) · Carcinoma, Squamous Cell (1) · Melanoma (1) · Pleural Effusion, Malignant (1) · Prostatic Neoplasms, Castration-Resistant (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms (8) · Neoplasms by Site (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Lung Diseases (7) · Bronchial Neoplasms (6) · Carcinoma, Bronchogenic (6) · Lung Neoplasms (5) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Anus Diseases (1) · Carcinoma, Squamous Cell (1)
durvalumab (2) · ALT-803 (1) · Carboplatin (1) · Cisplatin (1) · Drug Therapy (1) · Etoposide (1) · Pemetrexed (1) · Platinum Compounds (1) · Radiation (1) · Radiation Dose Hypofractionation (1) · Radiosurgery (1) · Ramucirumab (1) · Standard of Care (1) · abiraterone (1) · atezolizumab (1)
Washington University School of Medicine (2) · Alexander Chi (1) · Asan Medical Center (1) · MacroGenics (1) · Memorial Sloan Kettering Cancer Center (1) · NewLink Genetics Corporation (1) · Rachel Sanborn (1)
United States (5) · South Korea (2) · Australia (1) · Belgium (1) · China (1) · France (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1)
Daniel Morgensztern, M.D. (2) · Alexander Chi, MD (1) · Arun Rajan, M.D. (1) · Liudmila Schafer, M.D. (1) · Paul Romesser, MD (1) · Rachel Sanborn, MD (1)